Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2021-03-10

Clinical Trial Update: Ferric Citrate for the Treatment of Hyperphosphatemia in Patients With Chronic Kidney Disease Undergoing Hemodialysis [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial evaluating ferric citrate for treating hyperphosphatemia in patients with chronic kidney disease on hemodialysis has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Ferric citrate (ferric citrate)

Snippet

Sponsor: Panion & BF Biotech Inc. | Conditions: Hyperphosphatemia, End Stage Renal Disease | Phase 3 | Status: COMPLETED